Jakubowitz Law IS HERE TO HELP SHAREHOLDERS WHO PURCHASED Veru Inc. (VERU)

Veru is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that: 1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company’s interactions with the United States Food and Drug Administration; 2) defendants misled Veru's shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization (“EUA”) and even the submission of a New Drug Application without any further studies; and 3) the Company's filings concealed the true risks faced by Veru in gaining approval for its EUA request.

If you incurred a loss on VERU common stock purchased between May 11, 2022 and November 9, 2022, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Southern District of Florida, and our firm is reaching out to investors to discuss their legal rights.

If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.

You only have until February 6, 2023 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.